CN105560234A - Medicine composition for treating oral and maxillofacial inflammation - Google Patents
Medicine composition for treating oral and maxillofacial inflammation Download PDFInfo
- Publication number
- CN105560234A CN105560234A CN201610091522.6A CN201610091522A CN105560234A CN 105560234 A CN105560234 A CN 105560234A CN 201610091522 A CN201610091522 A CN 201610091522A CN 105560234 A CN105560234 A CN 105560234A
- Authority
- CN
- China
- Prior art keywords
- compound
- oral
- pharmaceutical composition
- maxillofacial surgery
- treatment
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 206010061218 Inflammation Diseases 0.000 title claims abstract description 21
- 230000004054 inflammatory process Effects 0.000 title claims abstract description 21
- 239000003814 drug Substances 0.000 title claims abstract description 10
- 239000000203 mixture Substances 0.000 title abstract description 5
- 229940079593 drug Drugs 0.000 title description 2
- 150000001875 compounds Chemical class 0.000 claims abstract description 26
- 239000003937 drug carrier Substances 0.000 claims abstract description 6
- 238000001356 surgical procedure Methods 0.000 claims description 16
- 239000008194 pharmaceutical composition Substances 0.000 claims description 15
- 241000305071 Enterobacterales Species 0.000 claims description 9
- 239000003085 diluting agent Substances 0.000 claims description 7
- 239000003795 chemical substances by application Substances 0.000 claims description 5
- 238000002360 preparation method Methods 0.000 claims description 5
- 230000005764 inhibitory process Effects 0.000 claims description 4
- GUBGYTABKSRVRQ-QKKXKWKRSA-N lactose group Chemical group OC1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@@H](O)[C@H](O2)CO)[C@H](O1)CO GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 claims description 4
- 239000011230 binding agent Substances 0.000 claims description 3
- 239000000314 lubricant Substances 0.000 claims description 3
- 239000003381 stabilizer Substances 0.000 claims description 3
- 229920000881 Modified starch Polymers 0.000 claims description 2
- 239000002775 capsule Substances 0.000 claims description 2
- 239000001913 cellulose Substances 0.000 claims description 2
- 229920002678 cellulose Polymers 0.000 claims description 2
- 239000008187 granular material Substances 0.000 claims description 2
- 208000015181 infectious disease Diseases 0.000 claims description 2
- 239000008101 lactose Substances 0.000 claims description 2
- 239000004531 microgranule Substances 0.000 claims description 2
- 235000019426 modified starch Nutrition 0.000 claims description 2
- 239000000843 powder Substances 0.000 claims description 2
- 239000003826 tablet Substances 0.000 claims description 2
- 230000000694 effects Effects 0.000 abstract description 2
- 244000052616 bacterial pathogen Species 0.000 abstract 1
- 229920001817 Agar Polymers 0.000 description 3
- 239000008272 agar Substances 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 0 CCC(CC[N+]CC(*C*)O)(*C)*CC1CI=ICC(C)C1 Chemical compound CCC(CC[N+]CC(*C*)O)(*C)*CC1CI=ICC(C)C1 0.000 description 2
- 230000002421 anti-septic effect Effects 0.000 description 2
- -1 antiseptic Substances 0.000 description 2
- 230000001580 bacterial effect Effects 0.000 description 2
- 230000003385 bacteriostatic effect Effects 0.000 description 2
- 235000016709 nutrition Nutrition 0.000 description 2
- 241000894006 Bacteria Species 0.000 description 1
- XTGCXRGCDSKHMG-UHFFFAOYSA-N C1C=CC=[I]C1 Chemical compound C1C=CC=[I]C1 XTGCXRGCDSKHMG-UHFFFAOYSA-N 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 230000000843 anti-fungal effect Effects 0.000 description 1
- 229940121375 antifungal agent Drugs 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000031018 biological processes and functions Effects 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 239000012050 conventional carrier Substances 0.000 description 1
- 239000012531 culture fluid Substances 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 210000004195 gingiva Anatomy 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 238000011081 inoculation Methods 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 239000007951 isotonicity adjuster Substances 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 239000012982 microporous membrane Substances 0.000 description 1
- 239000006916 nutrient agar Substances 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 230000003239 periodontal effect Effects 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 239000003643 water by type Substances 0.000 description 1
- 238000009736 wetting Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/438—The ring being spiro-condensed with carbocyclic or heterocyclic ring systems
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Preparation (AREA)
Abstract
The invention relates to a medicine composition for treating the oral and maxillofacial inflammation. The composition is prepared from an effective quantity of a compound and a pharmaceutically-acceptable carrier. The compound has the structure (shown in the description). The compound has a remarkable effect on pathogenic bacteria causing the oral and maxillofacial inflammation, and a clinically-effective new medicine composition can be developed.
Description
Technical field
The present invention relates to field of medicaments, specifically, the present invention relates to a kind of pharmaceutical composition for the treatment of oral and maxillofacial surgery inflammation.
Background technology
The teeth inflammation disease that oral and maxillofacial surgery inflammation is mainly caused by local factor.As failed treatment in time, inflammation can be diffused into periodontal membrane, alveolar bone and cementum by gingiva to deep layer and develop into oral and maxillofacial surgery inflammation.
Summary of the invention
The object of the present invention is to provide a kind of pharmaceutical composition for the treatment of oral and maxillofacial surgery inflammation.
In order to realize object of the present invention, the invention provides a kind of compound for the treatment of oral and maxillofacial surgery inflammation, this compound has having structure:
The present invention also provides a kind of pharmaceutical composition for the treatment of oral and maxillofacial surgery inflammation, and described pharmaceutical composition includes the compound of effective amount and pharmaceutically acceptable carrier, and described compound has having structure:
Preferably, described pharmaceutically acceptable carrier is diluent, disintegrating agent, binding agent, lubricant, stabilizing agent or corrigent.
Preferably, described diluent is sugar derivatives, starch derivatives or cellulose derivative.
Preferably, described diluent is lactose.
Preferably, described pharmaceutical composition is powder, microgranule, granule, capsule or tablet.
The present invention also provides the purposes of compound in the medicine of preparation treatment oral and maxillofacial surgery inflammation, and this compound has having structure:
Preferably, described infection is caused by day ditch dimension enterobacteria ATCC33028.
The present invention also provides the purposes of compound in the medicine of preparation vitro inhibition day ditch dimension enterobacteria ATCC33028, and this compound has having structure:
Term used herein " pharmaceutically acceptable " refers to not eliminate the biologic activity of compound as herein described or the material of character, as carrier or diluent.This kind of material is applied to and individual does not cause undesirable biological action or not with harmful way and any component interaction comprised in its compositions.
" pharmaceutically acceptable carrier " comprises any and all solvents as the term is employed herein, disperse medium, coating material, surfactant, antioxidant, antiseptic (such as antibacterial, antifungal), isotonic agent, absorption delay agent, salt, antiseptic, drug stabilizing agent, binding agent, excipient, disintegrating agent, lubricant, sweeting agent, correctives, dyestuff etc. and its combination, this is well-known to those skilled in the art (for example, see Remington'sPharmaceuticalSciences, 18thEd.MackPrintingCompany, 1990, pp.1289-1329).Except with except the inconsistent carrier of active component, consider to use any conventional carrier in treatment or pharmaceutical composition.
Compound of the present invention, for the pathogen Be very effective causing oral and maxillofacial surgery inflammation, can be developed to pharmaceutical composition effectively new clinically.
Detailed description of the invention
Below by way of the description of detailed description of the invention, the invention will be further described, but this is not limitation of the present invention, those skilled in the art are according to basic thought of the present invention, various amendment or improvement can be made, but only otherwise depart from basic thought of the present invention, all within the scope of the present invention.
The research of the purposes of experimental example the compounds of this invention in the medicine of preparation vitro inhibition day ditch dimension enterobacteria ATCC33028
Bacteriostatic test
Use following compounds, adopt filter paper enzyme classical in this area to carry out bacteriostatic test, wherein:
The structural formula of target compound is:
For examination strain day ditch dimension enterobacteria ATCC33028 purchased from Feng Shou (Shanghai) bio tech ltd.
Culture fluid
Nutrient agar and nutrient broth, purchased from Chen Yu experimental facilities company limited of BeiJing ZhongKe.
Test method
Day ditch dimension enterobacteria ATCC33028 is inoculated in agar plate nutritional solution plane, evenly gathers during inoculation.
Take target compound 0.01 gram, add 25000 ml sterile waters, ultrasonic 30 minutes, then the filtering with microporous membrane of 0.22 μm, obtained solution.The aseptic circular filter paper sheet of tweezer, sprays above-mentioned solution to complete wetting, is attached in the agar plate nutritional solution plane of inoculated bacteria.Agar plate is placed in the incubator of 37 DEG C, incubation 4 hours.Measure the diameter of bacterial restrain.Measure and average for 3 times.
1.4 result
The average diameter of the bacterial restrain of day ditch dimension enterobacteria ATCC33028 is 14.26mm, and this shows that target compound has the effect of extremely strong vitro inhibition day ditch dimension enterobacteria ATCC33028.
Claims (9)
1. treat a compound for oral and maxillofacial surgery inflammation, it is characterized in that, this compound has having structure:
2. treat a pharmaceutical composition for oral and maxillofacial surgery inflammation, it is characterized in that, described pharmaceutical composition includes the compound of effective amount and pharmaceutically acceptable carrier, and described compound has having structure:
3. the pharmaceutical composition for the treatment of oral and maxillofacial surgery inflammation according to claim 2, is characterized in that, described pharmaceutically acceptable carrier is diluent, disintegrating agent, binding agent, lubricant, stabilizing agent or corrigent.
4. the pharmaceutical composition for the treatment of oral and maxillofacial surgery inflammation according to claim 3, is characterized in that, described diluent is sugar derivatives, starch derivatives or cellulose derivative.
5. the pharmaceutical composition for the treatment of oral and maxillofacial surgery inflammation according to claim 4, is characterized in that, described diluent is lactose.
6. the pharmaceutical composition for the treatment of oral and maxillofacial surgery inflammation according to claim 3, is characterized in that, described pharmaceutical composition is powder, microgranule, granule, capsule or tablet.
7. the purposes of compound in the medicine of preparation treatment oral and maxillofacial surgery inflammation, it is characterized in that, this compound has having structure:
8. purposes according to claim 7, is characterized in that, described infection is tieed up enterobacteria ATCC33028 by day ditch and caused.
9. the purposes of compound in the medicine of preparation vitro inhibition day ditch dimension enterobacteria ATCC33028, it is characterized in that, this compound has having structure:
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610091522.6A CN105560234A (en) | 2016-02-18 | 2016-02-18 | Medicine composition for treating oral and maxillofacial inflammation |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610091522.6A CN105560234A (en) | 2016-02-18 | 2016-02-18 | Medicine composition for treating oral and maxillofacial inflammation |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN105560234A true CN105560234A (en) | 2016-05-11 |
Family
ID=55871259
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201610091522.6A Pending CN105560234A (en) | 2016-02-18 | 2016-02-18 | Medicine composition for treating oral and maxillofacial inflammation |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN105560234A (en) |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1994029317A1 (en) * | 1993-06-10 | 1994-12-22 | Merck & Co., Inc. | Process of making spirocycles and analogs thereof |
| WO2004092179A1 (en) * | 2003-04-14 | 2004-10-28 | Nippon Soda Co. Ltd. | Spiro derivative, production process, and antioxidant |
| WO2011047481A1 (en) * | 2009-10-23 | 2011-04-28 | Merck Frosst Canada Ltd. | Novel spiro compounds useful as inhibitors of stearoyl-coenzyme a delta-9 desaturase |
| WO2011141474A1 (en) * | 2010-05-12 | 2011-11-17 | Boehringer Ingelheim International Gmbh | Novel ccr2 receptor antagonists, method for producing the same, and use thereof as medicaments |
-
2016
- 2016-02-18 CN CN201610091522.6A patent/CN105560234A/en active Pending
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1994029317A1 (en) * | 1993-06-10 | 1994-12-22 | Merck & Co., Inc. | Process of making spirocycles and analogs thereof |
| WO2004092179A1 (en) * | 2003-04-14 | 2004-10-28 | Nippon Soda Co. Ltd. | Spiro derivative, production process, and antioxidant |
| WO2011047481A1 (en) * | 2009-10-23 | 2011-04-28 | Merck Frosst Canada Ltd. | Novel spiro compounds useful as inhibitors of stearoyl-coenzyme a delta-9 desaturase |
| WO2011141474A1 (en) * | 2010-05-12 | 2011-11-17 | Boehringer Ingelheim International Gmbh | Novel ccr2 receptor antagonists, method for producing the same, and use thereof as medicaments |
Non-Patent Citations (1)
| Title |
|---|
| AHMED H. ABDELAZEEM,ET AL.: "Novel pyrazolopyrimidine derivatives targeting COXs and iNOS enzymes; design, synthesis and biological evaluation as potential anti-inflammatory agents", 《EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES》 * |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Al-Waili | Investigating the antimicrobial activity of natural honey and its effects on the pathogenic bacterial infections of surgical wounds and conjunctiva | |
| CN104083364B (en) | A kind of pharmaceutical composition for the treatment of the infantile respiratory tract infection that enterobacter cloacae causes | |
| CN103975957B (en) | A kind of mixing formula formulation preparation method preventing and treating brown planthopper | |
| CN105198903A (en) | Pharmaceutical composition for treating acute upper respiratory infection | |
| CN105560234A (en) | Medicine composition for treating oral and maxillofacial inflammation | |
| CN104086541B (en) | A kind of pharmaceutical composition for the treatment of infantile respiratory tract infection | |
| CN105085503A (en) | Medicine composition for treating respiratory tract infection | |
| CN105997990B (en) | Purposes of the compound in the external medicine for suppressing C.perfringens ATCC 13124 is prepared | |
| CN105232542B (en) | A kind of pharmaceutical composition for the treatment of infantile pneumonia | |
| CN105348183A (en) | Pharmaceutical composition for treating gynecology-and-obstetrics postoperative low-fever symptom | |
| CN105294535A (en) | Pharmaceutical composition used for treating pelvic inflammation | |
| CN105748478B (en) | A kind of medicine treating infantile diarrhea | |
| CN105237542A (en) | Medicine composition for treating gynecological diseases | |
| CN105622619A (en) | Medicine composition for treating periodontitis | |
| CN105232550B (en) | A kind of pharmaceutical composition treating chronic pelvic inflammatory disease | |
| CN105348270B (en) | A kind of pharmaceutical composition for preventing and treating tooth body infections of dental pulp | |
| CN105732522A (en) | Medicine composition for treating periodontitis | |
| CN105125546A (en) | Medicine composition for treating postoperative wound infection | |
| CN105218460A (en) | A kind of pharmaceutical composition for the treatment of enteritis | |
| CN105853434A (en) | Medicinal composition for treating gingivitis in orthodontic children | |
| CN105232504A (en) | Medicine composition for treating infant recurrent respiratory tract infections | |
| CN105061331A (en) | Pharmaceutical composition for eliminating phlegm for children | |
| CN105330610A (en) | Medicine composition for treating gingivitis | |
| CN104000767A (en) | Female care solution and preparing method thereof | |
| CN106806367A (en) | A kind of pharmaceutical composition for treating infections after burn |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20160511 |
|
| RJ01 | Rejection of invention patent application after publication |